This study aimed to investigate the effects of small molecular weight deer antler collagen extract complex (NP-2007C) on skin moisturizing and improvement of skin wrinkles. In HaCaT cells, NP-2007C treatment significantly increased the contents of procollagen type I and hyaluronic acid (HA) as well as the gene expression levels of hyaluronic acid synthase 1 (HAS1), HAS2, filaggrin, and aquaporin 3 (AQP3). In hairless mice, the contents of collagen type I, HA, and ceramide significantly increased in the NP-2007C-fed group. In addition, when NP-2007C was treated in HaCaT cells irradiated with UVB, the activity of matrix metalloproteinase-1 (MMP-1) decreased, while the activities of superoxide dismutase (SOD), catalase (CAT), and glutathione peroxidase (GPx) increased. In the NP-2007C-fed group in hairless mice, skin moisture content increased, and transepidermal water loss (TEWL) decreased. Furthermore, wrinkle formation was improved in the NP-2007C-fed group in UVB-irradiated hairless mice, and the enzymatic activity of cytokines such as transforming growth factor-β (TGF-β), interleukin 1 beta (IL-1β), and IL-6 decreased. Therefore, the results of this study suggest that NP-2007C has sufficient development value as health functional food for improving skin health by suppressing UVB-induced oxidative stress and regulating skin moisturizing and wrinkle-related signaling pathways.
Osteoarthritis (OA) is a chronic, debilitating degenerative joint disease whose prevalence is rising markedly with the rapid aging of the global population. In this study, we investigated the chondroprotective efficacy of NP-2007, an enzymatically hydrolyzed low-molecular-weight collagen from Cervi cornu, using IL-1β-stimulated SW1353 human chondrocyte cells and a medial meniscal transection (MMT)-induced OA rat model. In SW1353 cells, NP-2007 considerably suppressed the expression of inflammatory mediators (iNOS, COX-2) and cytokines (TNF-α, IL-6) without cytotoxicity. Crucially, it restored matrix homeostasis by downregulating catabolic enzymes (MMP-3, MMP-13, and ADAMTS-5) and upregulating anabolic markers (COL2A1, aggrecan), a process associated with the modulation of the Wnt/β-catenin and phosphoinositide 3-kinase/protein kinase B/mammalian target of rapamycin (PI3K/Akt/mTOR) signaling pathways and the recovery of the master chondrogenic factor SOX9. These in vitro findings were consistent with the in vivo results from the MMT model, where oral administration of NP-2007 (50 and 200 mg/kg) for 8 weeks effectively preserved articular cartilage structure and proteoglycan content while markedly reducing serum levels of catabolic biomarkers, including MMP-13 and COMP. Collectively, our findings demonstrate that NP-2007 exerts potent chondroprotective effects by modulating the balance between cartilage degradation and synthesis, suggesting its potential as a therapeutic candidate for the management of OA.